Gynecological brachytherapy for postoperative endometrial cancer: dosimetric analysis (Ir-192 vs Co-60)

Introduction. Endovaginal brachytherapy treatment dosimetry differences were studied using Ir-192 or Co-60 sources for postoperative endometrial cancer. Materials and methods. A prospective descriptive study was conducted. Thirty-six dosimetry plans of different patients were studied (15 by Ir-192 and 21 by Co-60). Variables studied included D2cc Rectum, D2cc Bladder, D2cc Sigmoid, dose percentage at point 0 (applicator surface on the top of the cylinder) and dose percentage at point 1 (5 mm deep on the top of the cylinder). A comparative analysis was performed of the values obtained from each variable between Ir-192 and Co-60 treatments. We compared average of each variables between Iridium and Cobalt by T Student for independent samples (SPSS 22). Results. here were no significant differences on using Ir-192 or Co-60 by variables, except for dose percentage at point 1 in which we detected significant differences (Table 1). Discussion. Brachytherapy treatment dosimetry plans are similar using Ir-192 or Co-60, except dose percentage at point 1. In the scientific literature, some differences exist and there are some advantages in using cobalt (AU)

No disponible

Gynecological brachytherapy for postoperative endometrial cancer: dosimetric analysis (Ir-192 vs Co-60).

INTRODUCTION: Endovaginal brachytherapy treatment dosimetry differences were studied using Ir-192 or Co-60 sources for postoperative endometrial cancer. MATERIALS AND METHODS: A prospective descriptive study was conducted. Thirty-six dosimetry plans of different patients were studied (15 by Ir-192 and 21 by Co-60). Variables studied included D2cc Rectum, D2cc Bladder, D2cc Sigmoid, dose percentage at point 0 (applicator surface on the top of the cylinder) and dose percentage at point 1 (5 mm deep on the top of the cylinder). A comparative analysis was performed of the values obtained from each variable between Ir-192 and Co-60 treatments. We compared average of each variables between Iridium and Cobalt by T Student for independent samples (SPSS 22). RESULTS: There were no significant differences on using Ir-192 or Co-60 by variables, except for dose percentage at point 1 in which we detected significant differences (Table 1). Table 1 The results Variables Sources Iridium 192 Cobalt 60 D2cc Rectum (mean dose) [rank] 6.01 Gy [3.99-7.90] 5.28 Gy [3.87-6,34] D2cc Bladder (mean dose) [rank] 5.82 Gy [4.20-8.38] 5.05 Gy [2.23-6.95] D2cc Sigmoid (mean dose) [rank] 4.43 Gy [1.66-6.67] 2.33 Gy [0.60-4.28] Dose percentage at point 0a (mean) [rank] 210.74% [120.90-234.90] 204.75% [177.10-223] Dose percentage at point 1b (mean) [rank] 93.49% [87.30-100.60] 100.11% [96.70-102] aPoint 0: point to the applicator surface bPoint 1: point to 5 mm applicator surface DISCUSSION: Brachytherapy treatment dosimetry plans are similar using Ir-192 or Co-60, except dose percentage at point 1. In the scientific literature, some differences exist and there are some advantages in using cobalt.

Evaluation of toxicity of surgery and/or chemoirradiation treatment of uterine cervix cancer.

OBJECTIVE: To evaluate acute and chronic toxicity of chemoirradiation treatment (neoadjuvant, adjuvant and radical treatment) in patients diagnosed with cervix cancer. METHODS: From December 1999 to August 2007, 53 patients diagnosed with adenocarcinoma or squamous cell carcinoma of the uterine cervix received neoadjuvant, adjuvant or radical chemoirradiation. RESULTS: Acute gastrointestinal toxicity of grade 3 or more in 9 patients (17%) and haematological toxicity of grade 3 or more in 9 patients (17%). Chronic toxicity of grade 3 or more was shown in only 2 patients (4%). The most frequent toxicities were gastrointestinal toxicity and haematological toxicity. The most frequent chronic toxicities were gastrointestinal toxicity and vaginal toxicity. CONCLUSIONS: We report that the combined neoadjuvant, adjuvant or radical chemoirradiation treatment with weekly cisplatin chemotherapy (40 mg/m(2)/week) in patients diagnosed with cervix cancer is a well tolerated treatment and chronic and acute toxicity is low-grade. This treatment scheme has easy compliance.

Evaluation of toxicity of surgery and/or chemoirradiation treatment of uterine cervix cancer

OBJECTIVE: To evaluate acute and chronic toxicity of chemoirradiation treatment (neoadjuvant, adjuvant and radical treatment) in patients diagnosed with cervix cancer. METHODS: From December 1999 to August 2007, 53 patients diagnosed with adenocarcinoma or squamous cell carcinoma of the uterine cervix received neoadjuvant, adjuvant or radical chemoirradiation. RESULTS: Acute gastrointestinal toxicity of grade 3 or more in 9 patients (17%) and haematological toxicity of grade 3 or more in 9 patients (17%). Chronic toxicity of grade 3 or more was shown in only 2 patients (4%). The most frequent toxicities were gastrointestinal toxicity and haematological toxicity. The most frequent chronic toxicities were gastrointestinal toxicity and vaginal toxicity. CONCLUSIONS: We report that the combined neoadjuvant, adjuvant or radical chemoirradiation treatment with weekly cisplatin chemotherapy (40 mg/m(2)/week) in patients diagnosed with cervix cancer is a well tolerated treatment and chronic and acute toxicity is low-grade. This treatment scheme has easy compliance (AU)

No disponible

Re-irradiation to prevent ectopic bone formation after major hip surgery.

Ectopic bone formation may occur after total hip arthroplasty, but fortunately most patients are asymptomatic. Both pre-operative and post-operative radiotherapy are effective in prevention of ectopic bone formation. In the few patients who needed re-operation, we found that re-irradiation is possible and safe. This case report presents our experience with single dose reirradiation of the hip in an attempt to prevent post-operative ectopic bone formation.

Re-irradiation to prevent ectopic bone formation after major hip surgery

Ectopic bone formation may occur after total hip arthroplasty, but fortunately most patients are asymptomatic. Both pre-operative and post-operative radiotherapy are effective in prevention of ectopic bone formation. In the few patients who needed re-operation, we found that re-irradiation is possible and safe. This case report presents our experience with single dose reirradiation of the hip in an attempt to prevent post-operative ectopic bone formation (AU)

The usefulness of reirradiation in the treatment of pelvic recurrence of rectal and gynaecological tumours

La recidiva local de tumores pélvicos tras irradiación, aunque ha disminuido su incidencia gracias alas modernas técnicas de radioterapia, sigue produciéndose acompañada o no de metástasis a distancia.Además dicha recidiva ocasiona una gran morbilidad e incluso puede ser la causa de la muerte deestos pacientes. La selección del método de retratamiento a emplear representa un importante desafíoclínico. De todos los métodos de retratamiento posibles a utilizar, la reirradiación es uno de ellos.En esta revisión intentamos poner de manifiesto la complejidad del tratamiento en el caso de tumoresginecológicos y rectales recidivados y lo importante de considerar minuciosamente todas las alternativasterapéuticas que existen, para poder tomar una decisión final adecuada, sobre todo, si los pacientesya han sido previamente irradiados como tratamiento único o combinado de su tumor primario

Pelvic tumors recurrences have diminished with the modern radiation therapy techniques. However,they are still observed, with or without distant metastases, leading to a serious and even mortaldisease. The choice of an adequate therapy poses a clinical challenge. One of the procedures is therepetition of radiation therapy.In this review we manifest how complex is the treatment of gynecological and rectal tumorsrecidivations, and the importance of a detailed consideration of the available therapies in order tomake a decision, specially when the primary tumor has been previously irradiated, be it as onlytreatment or combined with other therapies (AU)